Roth Reaffirms Curis (CRIS) at Buy; Erivedge, Internal Pipeline Both Ongoing Strengths

February 24, 2014 11:33 AM

Roth Capital maintains its Buy rating and $10 price target on Curis (Nasdaq: CRIS) following Q4 results. The company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found